Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Preparing Prima Plus Stentless Heart Valve Postmarket Study

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences is preparing for a postmarket study to evaluate long-term effectiveness of the XenoLogiX anticalcification treatment used with its Prima Plus stentless porcine tissue heart valve following FDA approval of the valve Feb. 27.

You may also be interested in...



Medtronic launching Freestyle stentless porcine heart valve at a premium to St. Jude's Toronto SPV.

MEDTRONIC PRICING FREESTYLE VALVE AT PREMIUM TO ST. JUDE's TORONTO SPV, indicating a belief that the "advanced tissue technology" gives Medtronic an edge over its only competitor in the U.S. stentless porcine heart valve market. Premarket approval applications for the Medtronic and St. Jude stentless porcine heart valves cleared FDA on Nov. 25 and Nov. 24, respectively.

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel